Evidence map›Paper›PMID 34078304›Full record

Observational studyBMC cancer2021

Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.

Weelic Chong, Zhenchao Zhang, Rui Luo, Jian Gu, Jianqing Lin, Qiang Wei, Bingshan Li, Ronald Myers, Grace Lu-Yao, William Kevin Kelly and 2 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Weelic Chong *Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Zhenchao Zhang *Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Rui LuoDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Jian GuDepartment of Epidemiology, MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jianqing LinDepartment of Medicine, GW Cancer Center, George Washington University, Washington, DC, 20037, USA.
Qiang WeiDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, 37235, USA.
Bingshan LiDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, 37235, USA.
Ronald MyersDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Grace Lu-YaoDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
William Kevin KellyDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Chun WangDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. chun.wang@jefferson.edu.
Hushan YangDepartment of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. hushan.yang@jefferson.edu.
Sidney Kimmel Cancer Center · USThomas Jefferson University · USVanderbilt University · USGeorge Washington University · USThe University of Texas MD Anderson Cancer Center · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8M
Precision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2018 to 2020
$3.2M
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancerR01CA255792 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KELLY, WILLIAM K., LU-YAO, GRACE · 2021 to 2025
$3.2M
A population-based approach to single CTC analysis in metastatic breast cancer outcomeR01CA207468 · NCI · THOMAS JEFFERSON UNIVERSITY · PI YANG, HUSHAN · 2017 to 2022
$2.7M
NCI NIH HHS P20 CA233255NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA207468NCI NIH HHS R01 CA255792
6 · The paper itself

Abstract

backgroundThe neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and circulating tumor cells (CTCs) have been associated with survival in castration-resistant prostate cancer (CRPC). However, no study has examined the prognostic value of NLR and PLR in the context of CTCs.

methodsBaseline CTCs from mCRPC patients were enumerated using the CellSearch System. Baseline NLR and PLR values were calculated using the data from routine complete blood counts. The associations of CTC, NLR, and PLR values, individually and jointly, with progression-free survival (PFS) and overall survival (OS), were evaluated using Kaplan-Meier analysis, as well as univariate and multivariate Cox models.

resultsCTCs were detected in 37 (58.7%) of 63 mCRPC patients, and among them, 16 (25.4%) had ≥5 CTCs. The presence of CTCs was significantly associated with a 4.02-fold increased risk for progression and a 3.72-fold increased risk of death during a median follow-up of 17.6 months. OS was shorter among patients with high levels of NLR or PLR than those with low levels (log-rank P = 0.023 and 0.077). Neither NLR nor PLR was individually associated with PFS. Among the 37 patients with detectable CTCs, those with a high NLR had significantly shorter OS (log-rank P = 0.024); however, among the 26 patients without CTCs, the OS difference between high- and low-NLR groups was not statistically significant. Compared to the patients with CTCs and low NLR, those with CTCs and high levels of NLR had a 3.79-fold risk of death (P = 0.036). This association remained significant after adjusting for covariates (P = 0.031). Combination analyses of CTC and PLR did not yield significant results.

conclusionAmong patients with detectable CTCs, the use of NLR could further classify patients into different risk groups, suggesting a complementary role for NLR in CTC-based prognostic stratification in mCRPC.

Indexed as

AgedAged, 80 and overBlood PlateletsFollow-Up StudiesHumansKaplan-Meier EstimateLymphocyte CountLymphocytesMaleMiddle AgedNeoplastic Cells, CirculatingNeutrophilsPlatelet CountPrognosisProgression-Free SurvivalProspective StudiesCirculating tumor cellMetastatic castration-resistant prostate cancerNeutrophil-lymphocyte ratioPlatelet-lymphocyte ratioPrognosis

Identifiers

PMID34078304
PMCPMC8170812
OpenAlexW3164009857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.